Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-4. (Cancelled)
- 5. (Previously Presented) A method of treating diabetes with sulfonylurea secondary failure in a diabetic mammal in need thereof with sulfonylurea secondary failure which comprises: (a) testing if said mammal can no longer close an ATP-sensitive K+ channel due to stimulation by a sulfonylurea receptor 1-binding compound, and (b) administering to said mammal an effective amount of a dipeptidyl peptidase IV inhibitor.
 - 6. (Cancelled)
 - 7. (Cancelled)
- 8. (Previously Presented) A method of promoting insulin secretion in a diabetic patient in need thereof with sulfonylurea secondary failure which comprises: (a) testing if said patient can no longer close an ATP-sensitive K+ channel due to stimulation by a sulfonylurea receptor 1-binding compound, and (b) administering to the patient an effective amount of a dipeptidyl dipeptidase IV inhibitor.
- 9. (Previously Presented) The method according to Claim 5 wherein the sulfonylurea receptor 1-binding compound is a sulfonylurea compound and the sulfonylurea secondary failure is ascribable to the sulfonylurea compound.
- 10. (Previously Presented) The method according to Claim 5 wherein the sulfonylurea receptor 1-binding compound is a fast-acting insulin secretagogue and the sulfonylurea secondary failure is ascribable to the fast-acting insulin secretagogue.
- 11. (Previously Presented) The method according to Claim 8 wherein the sulfonylurea receptor 1-binding compound is a sulfonylurea compound and the sulfonylurea secondary failure is ascribable to the sulfonylurea compound.

- 12. (Previously Presented) The method according to Claim 8 wherein the sulfonylurea receptor 1-binding compound is a fast-acting insulin secretagogue and the sulfonylurea secondary failure is ascribable to the fast-acting insulin secretagogue.
- 13. (Withdrawn) The method according to claim 5 or 8, wherein the dipeptidyl peptidase IV inhibitor is 2-{[3-(aminomethyl)-2-isobutyl-4-phenyl-1-oxo-1,2-dihydro-6-isoquinolinyl]oxy}acetamide monohydrate.
- 14. (Withdrawn) The method according to claim 5 or 8, wherein the dipeptidyl peptidase IV inhibitor is (2S)-1-{[(3-hydroxy-1-adamantyl)amino]acetyl}-2-cyano-pyrrolidine.
- 15. (Previously Presented) The method according to claim 5 or 8, wherein the dipeptidyl peptidase IV inhibitor is the compound of the formula:

$$\begin{array}{c|c} F & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ & & & \\ \hline & & & \\ \hline & & & \\ & & & \\ \hline & \\ \hline &$$

or salt thereof.